Horizontal Tabs


leukemia cancers usually begin in the bone marrow and involves abnormal white blood cell production. leukemia has been reported to be sensitive to the effects of cannabinoids THC and CBD. These cannabinoids can be used to treat leukemia.

For more information, please, read the general cancer entry from the list of diseases in this website.



Wiki Entry

Top Right

Prescription Advice

Preclinical data suggests THC and CBD may be therapeutic in leukemia.

Given the nature of the disease, oral application or sublingual application may be beneficial.

For more information, please, read the general cancer entry from the list of diseases in this website.

Please follow generic prescription advice.

Please note that, while based on preclinical and/or clinical research, this prescription advice is solely intended as a guideline to help physicians determine the right prescription. We intend to continuously update our prescription advice based on patient and/or expert feedback. If you have information that this prescription advice is inaccurate, incomplete or outdated please contact us here.

Similar Entries

Horizontal Tabs

Literature Discussion

leukemia cells express functional CB1 and CB2 receptors (Moaddel et al., 2011).

THC is the most studied cannabinoid in leukemia treatment.

Studies with THC shown cytotoxic properties induced by apoptosis in leukemia cells (Herrera et al., 2005; Jia et al., 2006; Liu et al., 2008).

This apoptosis looks to be mediated by intrinsic pathways involving ceramide-dependent mitochondrial stimulation (Herrera et al., 2006; Lombard et al., 2005).

Also, other CB1/2 agonists showed leukemia cell growth and proliferation inhibition (Gallotta et al., 2010; Yrjölä et al., 2015).

CBD showed cell activation modulation too, but the mechanism failed to show G protein-coupled receptor pathways, suggesting unknown internal mechanisms (Giudice et al., 2007).


Gallotta, D., Nigro, P., Cotugno, R., Gazzerro, P., Bifulco, M., and Belisario, M.A. (2010). Rimonabant-induced apoptosis in leukemia cell lines: activation of caspase-dependent and -independent pathways. Biochem. Pharmacol. 80, 370–380.

Giudice, E.D., Rinaldi, L., Passarotto, M., Facchinetti, F., D’Arrigo, A., Guiotto, A., Carbonare, M.D., Battistin, L., and Leon, A. (2007). Cannabidiol, unlike synthetic cannabinoids, triggers activation of RBL-2H3 mast cells. J. Leukoc. Biol. 81, 1512–1522.

Herrera, B., Carracedo, A., Diez-Zaera, M., Guzmán, M., and Velasco, G. (2005). p38 MAPK is involved in CB2 receptor-induced apoptosis of human leukaemia cells. FEBS Lett. 579, 5084–5088.

Herrera, B., Carracedo, A., Diez-Zaera, M., Gómez del Pulgar, T., Guzmán, M., and Velasco, G. (2006). The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Exp. Cell Res. 312, 2121–2131.

Jia, W., Hegde, V.L., Singh, N.P., Sisco, D., Grant, S., Nagarkatti, M., and Nagarkatti, P.S. (2006). Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol. cancer Res. MCR 4, 549–562.

Liu, W.M., Scott, K.A., Shamash, J., Joel, S., and Powles, T.B. (2008). Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach. Leuk. Lymphoma 49, 1800–1809.

Lombard, C., Nagarkatti, M., and Nagarkatti, P.S. (2005). Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk. Res. 29, 915–922.

Moaddel, R., Rosenberg, A., Spelman, K., Frazier, J., Frazier, C., Nocerino, S., Brizzi, A., Mugnaini, C., and Wainer, I.W. (2011). Development and characterization of immobilized cannabinoid receptor (CB1/CB2) open tubular column for on-line screening. Anal. Biochem. 412, 85–91.

Yrjölä, S., Sarparanta, M., Airaksinen, A.J., Hytti, M., Kauppinen, A., Pasonen-Seppänen, S., Adinolfi, B., Nieri, P., Manera, C., Keinänen, O., et al. (2015). Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists. Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci. 67, 85–96.

Clinical Trials

There is one clinical case reporting a 14 year old patient with lymphoblastic leukemia with Philadelphia chromosome mutation treated with cannabis oil with significant dose-dependent decrease of leukemia cells (Singh and Bali, 2013).  


Singh, Y., and Bali, C. (2013). Cannabis Extract Treatment for Terminal Acute Lymphoblastic leukemia with a Philadelphia Chromosome Mutation. Case Rep. Oncol. 6, 585–592.